Moderna rebrands cancer vaccine work as therapy amid federal skepticism
Moderna and Merck are increasingly describing an mRNA-based cancer vaccine as an individualized neoantigen therapy as vaccine skepticism reshapes the US policy environment. The shift reflects both scientific positioning and a broader effort to shield promising research from political hostility toward vaccines.
